A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of two doses of bilastine (20 and 100 mg)
compared to bilastine 20 mg administered with ketoconazole 400 mg, moxifloxacin 400 mg, and
placebo. Subjects will receive each of the five study treatments in a crossover fashion
administered once daily for 4 days.
Phase:
Phase 1
Details
Lead Sponsor:
Faes Farma, S.A.
Treatments:
Ketoconazole Moxifloxacin Norgestimate, ethinyl estradiol drug combination